Inhibitions of several antineoplastic drugs on serum sialic acid levels in mice bearing tumors

Scientia Pharmaceutica

Volumn 81, Issue 1, 2013, Pages 223-231

  Lu, Da Yong ^a   Xu, Jing ^a   Lu, Ting Ren ^a   Wu, Hong Ying ^a   Xu, Bin ^b  

^a SHANGHAI UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Antineoplastic drugs; Cancer therapy; Cisplatin; Lycobetaine; Neoplasm metastasis; Nitrogen mustard; Probimane; Sialic acids

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; CISPLATIN; CORTISONE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; HARRINGTONINE; PROBIMANE; SIALIC ACID; THIOTEPA; VINBLASTINE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES TUMOR; BODY WEIGHT; CANCER INHIBITION; CONTROLLED STUDY; MOUSE; NEOPLASM; NONHUMAN; PROTEIN CONTENT; SOLID TUMOR; TUMOR GROWTH;

EID: 84875320345     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1209-18     Document Type: Article

References (27)

1. Siegel R, Ward E, Brawley O, Jamal A. Cancer statistics 2011. CA Cancer J Clin. 2011; 61: 212-236. http://dx.doi.org/10.3322/caac.20121
2. Lu DY, Lu TR, Cao S. Cancer metastases and clinical therapies. Cell Dev Biol. 2012; 1: e110. http://dx.doi.org/10.4172/2168-9296.1000e110
3. Pantel L, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004; 4: 448-456. http://dx.doi.org/10.1038/nrc1370
4. Klein CA. The metastasis cascade. Science. 2008; 321: 1785-1787. http://dx.doi.org/10.1126/science.1164853
5. Mina LA, Sledge GW. Rethinking the metastatic cascade as a therapeutic target. Nat Rev Clin Oncol. 2011; 8: 325-332. http://dx.doi.org/10.1038/nrclinonc.2011.59
6. Lu DY, Lu TR. Antimetastatic activities and mechanisms of Bisdioxopiperazine compounds. Anticancer Agents Medicinal Chem. 2010; 10: 564-570. http://dx.doi.org/10.2174/187152010793498654
7. Lu DY, Lu TR, Wu HY. Antimetastatic therapy targeting aberrant sialylation profiles in cancer cells. Drug Ther Stud. 2011; 1: e12. http://dx.doi.org/10.4081/dts.2011.e12
8. Lu DY, Lu TR, Wu HY. Development of antimetastatic drugs by targeting tumor sialic acids. Sci Pharm. 2012; 80: 497-508. http://dx.doi.org/10.3797/scipharm.1205-01
9. Varki NM, Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest. 2007; 87: 851-857. http://dx.doi.org/10.1038/labinvest.3700656
10. Varki A. Sialic acids in human health and disease. Trend Mol Med. 2008: 14: 351-360. http://dx.doi.org/10.1016/j.molmed.2008.06.002
11. Taurumi KI, Dawes ML. Serum sialic acid levels in mice with neoplasms. Cancer Res.1958; 18: 575-577. http://www.ncbi.nlm.nih.gov/pubmed/13547052
12. Kimura A, Nagai Y, Taurumi KI, Kawashima Y, Sato H. Hexosamine and sialic acid contents in cells. Nature.1961; 191: 596. http://dx.doi.org/10.1038/191596a0
13. Yogeeswaran G, Salk PL. Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science. 1981; 212: 1514-1516. http://dx.doi.org/10.1126/science.7233237
14. Nakamori S, Kameyama M, Imaoka. S, Furukawa H, Ishikawa O, Sasaki Y, Kabuto T, Iwanaga T, Matsushita Y, Irimura T. Increased expression of sialyl LewisX antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res. 1993; 53: 3632-3637. http://www.ncbi.nlm.nih.gov/pubmed/8101764
15. Kannagi R. Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J. 1997; 14: 577-583. http://dx.doi.org/10.1023/A:1018532409041
16. Peracaula R, Tabares G, Lopez-Ferrer A, Brossmer R, de Bolos C, de Llorens R. Role of sialyltransferases involved in the biosynthesis of Lewis antigens in human pancreatic tumour cells. Glycoconj J. 2005; 22: 135-144. http://dx.doi.org/10.1007/s10719-005-0734-2
17. Lu DY, Cao JY. Structural aberration of cellular sialic acids and their functions in cancer. J Shanghai Univ (Eng). 2001; 5: 164-170.
18. Miyagi T, Wada T, Yamaguchi K, Tata K. Sialidase and malignancy: a minireview. Glycoconj J. 2004; 20: 189-198. http://dx.doi.org/10.1023/B:GLYC.0000024250.48506.bf
19. Miyagi T, Wada T, Yamaguchi K, Shiozaki K, Sato I, Kakugawa Y, Yamanami H, Fujiya T. Human sialidase as a cancer marker. Proteomics.2008; 8: 3303-3311. http://dx.doi.org/10.1002/pmic.200800248
20. Angata T, Varki A. Chemical diversity in the sialic acids and related α-keto acids: an evolutionary perspective. Chem Rev. 2002; 102: 439-469. http://dx.doi.org/10.1021/cr000407m
21. Skoza L, Mohos S. Stable thiobarbituric acid chromophore with dimethyl sulphoxide, application to sialic acid assay in analytical de-O-acetylation. Biochem J. 1976; 159: 457-462. http://www.ncbi.nlm.nih.gov/pubmed/1008810
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin-phenol reagent. J Biol Chem.1953; 193: 265-275. http://www.ncbi.nlm.nih.gov/pubmed/14907713
23. Lu DY, Xu B, Ding J. Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo. BMC Pharmacol. 2004; 4: 32. http://dx.doi.org/10.1186/1471-2210-4-32
24. Lu DY, Wu FG, Shen ZM, Lu TR, Wu HY, Che JY, Xu B. Different spontaneous pulmonary metastasis inhibitions against Lewis lung carcinoma in mice by Bisdioxopiperazine compounds of different treatment schedules. Sci Pharm. 2010; 78: 13-20. http://dx.doi.org/10.3797/scipharm.0910-16
25. Liu J, Yang SL, Xu B. Characteristics of the interaction of lycobetaine with DNA. Acta Pharmacol Sin. 1989; 10: 437-442. http://www.ncbi.nlm.nih.gov/pubmed/2618733
26. Thejass P, Kuttan G. Antimetastatic activity of Sulforaphane. Life Sci. 2006; 78: 3043-3050. http://dx.doi.org/10.1016/j.lfs.2005.12.038
27. Lee SJ, Chung IM, Kim MY, Park KD, Park WH, Moon HI. Inhibition of lung metastasis in mice by Oligonol. Phytother Res. 2009; 23: 1043-1046. http://dx.doi.org/10.1002/ptr.2810